Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN89,5-0,98
Msft0,10
Nokia4,36054,4495-1,46
IBM-0,45
Daimler AG47,44547,455-1,57
PFE0,61
15.06.2019 2:00:00
Indexy online
AD Index online
select
AD Index online
 

  • 14.06.2019 22:00:00
Arena Pharmaceut Rg (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
55,32 -2,09 -1,18 493 996
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 16.06.2019
Popis společnosti
Obecné informace
Název společnostiArena Pharmaceuticals, Inc.
TickerARNA
Kmenové akcie:Ordinary Shares
RICARNA.O
ISINUS0400476075
Prioritní akcieConv. Pref. Shrs Series B
Poslední známé roční výsledky31.12.2018
Poslední známé čtvrtletní výsledky31.03.2019
Počet zaměstnanců k 15.02.2019 194
Akcie v oběhu k 03.05.2019 49 570 066
Počet akcionářů k 31.12.2018 65
MěnaUSD
Kontaktní informace
Ulice6154 Nancy Ridge Dr
MěstoSAN DIEGO
PSČ92121-3223
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon18 584 537 200
Fax18584537210

Business Summary: Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).
Financial Summary: BRIEF: For the three months ended 31 March 2019, Arena Pharmaceuticals, Inc. revenues increased from $1.8M to $801.1M. Net income before extraordinary items totaled $620.1M vs. loss of $31.1M. Revenues reflect Royalty revenue increase of 34% to $973K. Net Income reflects Interest income increase from $774K to $6.5M (income), Interest expense decrease of 16% to $1.2M (expense), Other income increase of 33% to $711K (income).
Odvětvová klasifikace
TRBC2012Biotechnology & Medical Research - NEC
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
NAICSDrug, Drug Proprietaries and Druggists' Sundries Wholesalers
SICPharmaceutical Preparations
SICCommercial Physical Research
SICDrugs/proprietaries/sundries



  • Poslední aktualizace: 16.06.2019
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Independent Chairman of the BoardTina Nova6401.01.2017
President, Chief Executive Officer, DirectorAmit Munshi5015.06.201611.05.2016
Chief Financial Officer, Executive Vice PresidentKevin Lind42
Executive Vice President, General Counsel, SecretarySteven Spector53
Executive Vice President and Chief Business OfficerVincent Aurentz5015.08.201615.08.2016
Executive Vice President - Research & Development, Chief Medical OfficerPreston Klassen4920.03.201720.03.2017
Executive Vice President and Chief Commercial OfficerRobert Lisicki-26.11.201826.11.2018
Senior Vice President - Medical AffairsPaul Audhya-26.11.201826.11.2018